Annual Accounts Receivable
$1.78 M
+$424.00 K+31.36%
December 31, 2023
Summary
- As of February 7, 2025, ABUS annual accounts receivable is $1.78 million, with the most recent change of +$424.00 thousand (+31.36%) on December 31, 2023.
- During the last 3 years, ABUS annual accounts receivable has risen by +$464.00 thousand (+35.37%).
- ABUS annual accounts receivable is now -46.48% below its all-time high of $3.32 million, reached on December 31, 2010.
Performance
ABUS Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$1.61 M
-$159.00 K-9.00%
September 30, 2024
Summary
- As of February 7, 2025, ABUS quarterly accounts receivable is $1.61 million, with the most recent change of -$159.00 thousand (-9.00%) on September 30, 2024.
- Over the past year, ABUS quarterly accounts receivable has dropped by -$531.00 thousand (-24.82%).
- ABUS quarterly accounts receivable is now -79.59% below its all-time high of $7.88 million, reached on March 31, 2017.
Performance
ABUS Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ABUS Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +31.4% | -24.8% |
3 y3 years | +35.4% | +18.9% |
5 y5 years | +24.1% | +18.9% |
ABUS Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +97.5% | -39.6% | +78.9% |
5 y | 5-year | at high | +97.5% | -39.6% | +78.9% |
alltime | all time | -46.5% | +1418.0% | -79.6% | +1274.4% |
Arbutus Biopharma Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $1.61 M(-9.0%) |
Jun 2024 | - | $1.77 M(-17.4%) |
Mar 2024 | - | $2.14 M(+20.4%) |
Dec 2023 | $1.78 M(+31.4%) | $1.78 M(-18.2%) |
Sep 2023 | - | $2.17 M(-16.9%) |
Jun 2023 | - | $2.61 M(-1.9%) |
Mar 2023 | - | $2.66 M(+97.0%) |
Dec 2022 | $1.35 M(+50.4%) | $1.35 M(-26.3%) |
Sep 2022 | - | $1.83 M(-6.9%) |
Jun 2022 | - | $1.97 M(+50.0%) |
Mar 2022 | - | $1.31 M(+46.1%) |
Dec 2021 | $899.00 K(-31.5%) | $899.00 K(-46.1%) |
Sep 2021 | - | $1.67 M(+28.4%) |
Jun 2021 | - | $1.30 M(+2.6%) |
Mar 2021 | - | $1.26 M(-3.6%) |
Dec 2020 | $1.31 M(+9.0%) | $1.31 M(+22.0%) |
Sep 2020 | - | $1.07 M(-3.0%) |
Jun 2020 | - | $1.11 M(+3.4%) |
Mar 2020 | - | $1.07 M(-11.0%) |
Dec 2019 | $1.20 M(-15.9%) | $1.20 M(-51.6%) |
Sep 2019 | - | $2.49 M(+62.5%) |
Jun 2019 | - | $1.53 M(+65.9%) |
Mar 2019 | - | $923.00 K(-35.5%) |
Dec 2018 | $1.43 M(+256.0%) | $1.43 M(+166.0%) |
Sep 2018 | - | $538.00 K(-59.3%) |
Jun 2018 | - | $1.32 M(+83.9%) |
Mar 2018 | - | $719.00 K(+78.9%) |
Dec 2017 | $402.00 K(+47.3%) | $402.00 K(-52.5%) |
Sep 2017 | - | $846.00 K(-18.8%) |
Jun 2017 | - | $1.04 M(-86.8%) |
Mar 2017 | - | $7.88 M(+2785.7%) |
Dec 2016 | $273.00 K(-72.9%) | $273.00 K(-30.9%) |
Sep 2016 | - | $395.00 K(-13.4%) |
Jun 2016 | - | $456.00 K(+34.1%) |
Mar 2016 | - | $340.00 K(-66.3%) |
Dec 2015 | $1.01 M(-47.0%) | $1.01 M(-54.0%) |
Sep 2015 | - | $2.19 M(-65.4%) |
Jun 2015 | - | $6.33 M(+38.7%) |
Mar 2015 | - | $4.56 M(+139.8%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2014 | $1.90 M(+1526.5%) | $1.90 M(-9.1%) |
Sep 2014 | - | $2.09 M(+600.3%) |
Jun 2014 | - | $299.00 K(-80.3%) |
Mar 2014 | - | $1.52 M(+1200.0%) |
Dec 2013 | $117.00 K(-89.1%) | $117.00 K(-97.1%) |
Sep 2013 | - | $3.98 M(+141.8%) |
Jun 2013 | - | $1.65 M(+12.2%) |
Mar 2013 | - | $1.47 M(+36.5%) |
Dec 2012 | $1.07 M(+24.6%) | $1.07 M(-48.3%) |
Sep 2012 | - | $2.08 M(+8.0%) |
Jun 2012 | - | $1.93 M(-21.2%) |
Mar 2012 | - | $2.44 M(+183.4%) |
Dec 2011 | $862.60 K(-74.0%) | $862.60 K(-61.0%) |
Sep 2011 | - | $2.21 M(-52.8%) |
Jun 2011 | - | $4.68 M(+37.0%) |
Mar 2011 | - | $3.42 M(+3.0%) |
Dec 2010 | $3.32 M(+230.0%) | $3.32 M(+61.5%) |
Sep 2010 | - | $2.05 M(+121.8%) |
Jun 2010 | - | $926.60 K(+26.1%) |
Mar 2010 | - | $734.60 K(-26.9%) |
Dec 2009 | $1.01 M(+93.5%) | $1.01 M(-11.3%) |
Sep 2009 | - | $1.13 M(-10.5%) |
Jun 2009 | - | $1.27 M(+20.5%) |
Mar 2009 | - | $1.05 M(+102.3%) |
Dec 2008 | $519.70 K(-71.7%) | $519.70 K(-73.4%) |
Sep 2008 | - | $1.95 M(-14.1%) |
Jun 2008 | - | $2.27 M(+230.8%) |
Mar 2008 | - | $687.10 K(-62.6%) |
Dec 2007 | $1.84 M(+204.0%) | $1.84 M(-28.6%) |
Sep 2007 | - | $2.57 M(+120.4%) |
Jun 2007 | - | $1.17 M |
Dec 2006 | $604.60 K(+132.5%) | - |
Dec 2005 | $260.00 K(-85.6%) | - |
Dec 2004 | $1.80 M(+435.2%) | - |
Dec 2003 | $336.30 K(-79.8%) | - |
Dec 2001 | $1.66 M(+1172.9%) | - |
Dec 2000 | $130.60 K(-30.1%) | - |
Dec 1999 | $186.80 K(-12.1%) | - |
Dec 1998 | $212.40 K | - |
FAQ
- What is Arbutus Biopharma annual accounts receivable?
- What is the all time high annual accounts receivable for Arbutus Biopharma?
- What is Arbutus Biopharma annual accounts receivable year-on-year change?
- What is Arbutus Biopharma quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly accounts receivable year-on-year change?
What is Arbutus Biopharma annual accounts receivable?
The current annual accounts receivable of ABUS is $1.78 M
What is the all time high annual accounts receivable for Arbutus Biopharma?
Arbutus Biopharma all-time high annual accounts receivable is $3.32 M
What is Arbutus Biopharma annual accounts receivable year-on-year change?
Over the past year, ABUS annual accounts receivable has changed by +$424.00 K (+31.36%)
What is Arbutus Biopharma quarterly accounts receivable?
The current quarterly accounts receivable of ABUS is $1.61 M
What is the all time high quarterly accounts receivable for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly accounts receivable is $7.88 M
What is Arbutus Biopharma quarterly accounts receivable year-on-year change?
Over the past year, ABUS quarterly accounts receivable has changed by -$531.00 K (-24.82%)